Arlington Trust Co LLC Increases Stock Holdings in Encompass Health Corporation (NYSE:EHC)

Arlington Trust Co LLC boosted its position in shares of Encompass Health Corporation (NYSE:EHC) by 22.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 671 shares of the company’s stock after acquiring an additional 125 shares during the period. Arlington Trust Co LLC’s holdings in Encompass Health were worth $68,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Colonial Trust Co SC bought a new position in Encompass Health in the 4th quarter valued at $29,000. Transce3nd LLC bought a new position in shares of Encompass Health in the fourth quarter worth $40,000. CBIZ Investment Advisory Services LLC raised its position in shares of Encompass Health by 38.7% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company’s stock worth $42,000 after buying an additional 127 shares in the last quarter. Signaturefd LLC boosted its stake in Encompass Health by 21.6% during the fourth quarter. Signaturefd LLC now owns 704 shares of the company’s stock valued at $65,000 after buying an additional 125 shares during the period. Finally, C M Bidwell & Associates Ltd. grew its position in Encompass Health by 73.6% during the fourth quarter. C M Bidwell & Associates Ltd. now owns 750 shares of the company’s stock worth $69,000 after buying an additional 318 shares in the last quarter. Institutional investors own 97.25% of the company’s stock.

Encompass Health Trading Down 1.2%

Shares of EHC opened at $118.92 on Thursday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.06 and a current ratio of 1.06. Encompass Health Corporation has a fifty-two week low of $82.74 and a fifty-two week high of $123.13. The firm has a 50 day moving average price of $118.92 and a 200-day moving average price of $105.07. The firm has a market cap of $11.99 billion, a price-to-earnings ratio of 24.57, a PEG ratio of 2.45 and a beta of 0.88.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.18. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a net margin of 8.97% and a return on equity of 17.63%. The company’s revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.12 earnings per share. As a group, equities research analysts forecast that Encompass Health Corporation will post 4.8 earnings per share for the current year.

Encompass Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Tuesday, July 1st will be paid a $0.17 dividend. The ex-dividend date is Tuesday, July 1st. This represents a $0.68 dividend on an annualized basis and a yield of 0.57%. Encompass Health’s dividend payout ratio (DPR) is currently 14.05%.

Analysts Set New Price Targets

EHC has been the topic of several recent analyst reports. Truist Financial reaffirmed a “buy” rating and issued a $135.00 price target (up previously from $116.00) on shares of Encompass Health in a report on Monday, April 28th. UBS Group upped their price objective on shares of Encompass Health from $117.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, April 28th. Barclays lifted their target price on shares of Encompass Health from $118.00 to $129.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. Royal Bank Of Canada increased their price target on shares of Encompass Health from $110.00 to $125.00 and gave the stock an “outperform” rating in a report on Monday, April 28th. Finally, KeyCorp lifted their price objective on shares of Encompass Health from $122.00 to $135.00 and gave the stock an “overweight” rating in a report on Tuesday, May 27th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $127.00.

Insider Buying and Selling at Encompass Health

In other Encompass Health news, CEO Mark J. Tarr sold 118,384 shares of the stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the completion of the sale, the chief executive officer owned 527,070 shares of the company’s stock, valued at $64,054,817.10. This represents a 18.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Elissa Joy Charbonneau sold 4,279 shares of the firm’s stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $116.61, for a total value of $498,974.19. Following the completion of the sale, the insider directly owned 11,958 shares in the company, valued at $1,394,422.38. The trade was a 26.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 132,663 shares of company stock worth $16,034,082. 2.00% of the stock is currently owned by insiders.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.